ijms-logo

Journal Browser

Journal Browser

Liver Diseases: From Pathophysiology to Novel Therapeutic Approaches

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 145

Special Issue Editor


E-Mail Website
Guest Editor
UCL Medical School, London, UK
Interests: liver disease; molecular mechanisms; treatments for liver disease; somatic cell therapy; ATMP; medical device; molecular approaches; molecular signatures

Special Issue Information

Dear Colleagues,

The prevalence of liver disease is increasing worldwide. More than sixty years ago, Thomas Starzl performed the first whole-organ liver transplant, which was successfully repeated in the UK and Europe within 5 years. Transplantation can be curative for many patients; however, donor organs are limited and many patients do not receive this curative treatment. Nonetheless, new treatments for liver disease are crucial as liver disease is widespread and growing. Recent advances in understanding the pathophysiology of many liver diseases offer hope for many new therapeutic approaches. With a better understanding of disease pathology at the molecular level, ideas that were a pipe dream 20 years ago are becoming a reality today. Examples in liver disease include anti-fibrotic and cirrhosis-resolving pharmaceuticals. Novel cell therapies in liver cancer include immune modulation therapies and somatic cell therapies, or the use of RNA nanomedicine, wherein gene or protein expression is altered without a corresponding alteration in DNA sequences. Moreover, several delivery technologies are required for these new treatments to be used in patients, whether they be medical devices, nano-carriers, GalNAc based conjugates that target the asialo-glycoprotein receptor, cell and organoid cryopreservation, or cell transplantation into a stem cell niche.

This Special Issue aims to bring together new technological approaches to produce and deliver novel therapies for liver disease as well as to further investigate the molecular patterns associated with liver disease using appropriate “omics” for exploring liver disease pathology further.

Dr. Clare Selden
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver disease molecular mechanisms treatments for liver disease somatic cell therapy
  • ATMP medical device molecular approaches
  • molecular signatures
  • RNA therapies
  • “omics” for liver disease pathobiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

27 pages, 2779 KiB  
Article
Cinnamic Acid: A Shield Against High-Fat-Diet-Induced Liver Injury—Exploring Nrf2’s Protective Mechanisms
by Asmahan Taher Alahdal, Laila Naif Al-Harbi, Ghedeir M. Alshammari, Ali Saleh and Mohammed Abdo Yahya
Int. J. Mol. Sci. 2025, 26(16), 7940; https://doi.org/10.3390/ijms26167940 (registering DOI) - 17 Aug 2025
Abstract
This study investigated the hepatoprotective effects of cinnamic acid (CA) against liver injury and fat accumulation induced by a high-fat diet (HFD), focusing on the role of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling. Male Wistar rats were divided into six [...] Read more.
This study investigated the hepatoprotective effects of cinnamic acid (CA) against liver injury and fat accumulation induced by a high-fat diet (HFD), focusing on the role of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling. Male Wistar rats were divided into six groups: a control group receiving carboxymethylcellulose; a CA control group (40 mg/kg); an HFD group; two HFD groups treated with CA (20 mg/kg or 40 mg/kg); and a HFD group co-treated with CA (40 mg/kg) and brusatol (2 mg/kg, i.p.), a selective Nrf2 inhibitor. CA was administered orally, and brusatol intraperitoneally, both twice per week for twelve weeks. CA had no effect on serum glucose or insulin but improved serum and hepatic profiles in HFD rats. It also attenuated liver vacuolization and normalized serum levels of ALT, AST, and γ-GT. CA also reduced hepatic apoptosis by increasing Bcl2 and reducing Bax and caspase-3 levels. CA mitigated oxidative stress by reducing MDA and enhancing SOD and GSH levels. It suppressed inflammatory mediators, including TNF-α, IL-6, and NF-κB. CA also downregulated SREBP1, FAS, ACC-1, and Keap1 while increasing mRNA and nuclear translocation of Nrf2. All these effects were dose-dependent. Similar molecular effects of CA were also seen in control rats while CA protection in HFD rats was abolished with brusatol indicating Nrf2-dependency. Such findings highlight CA as a promising nutraceutical candidate for preventing HFD-induced liver injury. Further studies are warranted to explore its clinical applicability in metabolic liver diseases. Full article
(This article belongs to the Special Issue Liver Diseases: From Pathophysiology to Novel Therapeutic Approaches)
Show Figures

Figure 1

Back to TopTop